Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spironolactone vs Prednisolone in steroid-naive boys with DMD
NCT03777319Phase 1Terminated
- Sponsor
- Kevin Flanigan (Nationwide Children's Hospital)
- Start
- Dec 2018
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of spironolactone in Duchenne muscular dystrophy (DMD) (2 arms), sponsored by Kevin Flanigan (Nationwide Children's Hospital). Primary endpoints: Time to Complete a 100 Meter Timed Test at 6 months and Safety Monitored Through Regular Review of Electrolytes at 6 months. Started Dec 2018; status: terminated.
02
Drugs
spironolactone
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT03777319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03777319.